Lexeo Therapeutics operates under the executive leadership of Nolan Townsend, who serves as the Chief Executive Officer and a member of the Board of Directors. Bringing extensive senior operational experience across the biopharmaceutical and gene therapy sectors, he directs the company's corporate strategy, clinical trial execution, and the advancement of its pipeline targeting genetically defined cardiovascular and central nervous system diseases.